Idec Zevalin
Executive Summary
FDA's Oncologic Drugs Advisory Committee is expected to consider the radioimmunotherapy Zevalin (ibritumomab tiuxetan) for treatment of relapsed or refractory, low grade or follicular non-Hodgkin's lymphoma during the first quarter, Idec CEO William Rastetter, PhD, tells the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 11. The next scheduled oncologics committee meeting is in March